{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:57:00Z","timestamp":1779911820404,"version":"3.53.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00228-021-03270-2","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:04:01Z","timestamp":1643328241000},"page":"733-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety profile of COVID-19 drugs in a real clinical setting"],"prefix":"10.1007","volume":"78","author":[{"given":"Mei Nee","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitry","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-489X","authenticated-orcid":false,"given":"Sangeeta Pilkhwal","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"3","key":"3270_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cmrp.2020.05.013","volume":"10","author":"M Ven Venkatasubbaiah","year":"2020","unstructured":"Ven Venkatasubbaiah M, Reddy PD, Satyanarayana SV (2020) Literature-based review of the drugs used for the treatment of COVID-19. Current medicine research and practice 10(3):100\u2013109. https:\/\/doi.org\/10.1016\/j.cmrp.2020.05.013","journal-title":"Current medicine research and practice"},{"key":"3270_CR2","unstructured":"WHO (2021) W.H.O. WHO coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/. Accessed 14 June 2021"},{"key":"3270_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, Parida S, Lingaraju MC et al (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479\u20131508","journal-title":"Pharmacol Rep"},{"key":"3270_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173890","volume":"895","author":"P Tarighi","year":"2021","unstructured":"Tarighi P, Eftekhari S, Chizari, et al (2021) A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol 895:173890. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173890","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3270_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s11739-020-02586-8","volume":"16","author":"G Crescioli","year":"2021","unstructured":"Crescioli G, Brilli V, Lanzi C et al (2021) Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug\u2013drug interactions. Intern Emerg Med 16(3):697\u2013710. https:\/\/doi.org\/10.1007\/s11739-020-02586-8","journal-title":"Intern Emerg Med"},{"key":"3270_CR6","doi-asserted-by":"publisher","unstructured":"Desai MK (2020) Pharmacovigilance and assessment of drug safety reports during COVID 19. Perspectives in clinical research 11(3):128. https:\/\/doi.org\/10.4103\/picr.PICR_171_20","DOI":"10.4103\/picr.PICR_171_20"},{"issue":"17","key":"3270_CR7","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1111\/febs.15375","volume":"287","author":"CL Atzrodt","year":"2020","unstructured":"Atzrodt CL, Maknojia I, McCarthy RDP et al (2020) A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J 287(17):3633\u20133650. https:\/\/doi.org\/10.1111\/febs.15375","journal-title":"FEBS J"},{"key":"3270_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2020","unstructured":"Yousefi H, Mashouri L, Okpechi SC et al (2020) Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol 183:114296. https:\/\/doi.org\/10.1016\/j.bcp.2020.114296","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3270_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13476","volume":"33","author":"\u00dc T\u00fcrsen","year":"2020","unstructured":"T\u00fcrsen \u00dc, T\u00fcrsen B, Lotti T (2020) Cutaneous s\u0131de-effects of the potential COVID-19 drugs. Dermatol Ther 33(4):e13476. https:\/\/doi.org\/10.1111\/dth.13476","journal-title":"Dermatol Ther"},{"key":"3270_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699949","volume":"12","author":"D Liu","year":"2021","unstructured":"Liu D, Zeng X, Ding Z et al (2021) Adverse cardiovascular effects of anti-COVID-19 drugs. Front Pharmacol 12:699949. https:\/\/doi.org\/10.3389\/fphar.2021.699949","journal-title":"Front Pharmacol"},{"issue":"8","key":"3270_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"3270_CR12","doi-asserted-by":"publisher","unstructured":"Zengin R, Sarikaya ZT, Karada\u011f Net al (2020) Adverse cardiac events related to hydroxychloroquine prophylaxis and treatment of COVID-19. Infect Dis Clin Microbiol 2(1):24\u201326. https:\/\/doi.org\/10.36519\/idcm.2020.0012","DOI":"10.36519\/idcm.2020.0012"},{"issue":"6","key":"3270_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8415","volume":"12","author":"R Abdelmaseih","year":"2020","unstructured":"Abdelmaseih R, AbdelmasihR HM et al (2020) Serious adverse events associated with hydroxychloroquine amidst COVID-19 pandemic: case series and literature review. Cureus 12(6):e8415. https:\/\/doi.org\/10.7759\/cureus.8415","journal-title":"Cureus"},{"issue":"6","key":"3270_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","volume":"102","author":"MB Falc\u00e3o","year":"2020","unstructured":"Falc\u00e3o MB, Cavalcanti LP, Filho NMF et al (2020) Case report: hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19. Am J Trop Med Hyg 102(6):1214\u20131216. https:\/\/doi.org\/10.4269\/ajtmh.20-0276","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"3270_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1536\/ihj.20-271","volume":"61","author":"Y Kang","year":"2020","unstructured":"Kang Y, Wang H, Chen H et al (2020) Suspected hydroxychloroquine-induced sinus bradycardia and QTc prolongation in a patient with COVID-19. Int Heart J 61(5):1056\u20131058. https:\/\/doi.org\/10.1536\/ihj.20-271","journal-title":"Int Heart J"},{"key":"3270_CR16","doi-asserted-by":"publisher","unstructured":"Davoodi L, Jafarpour H, Kazeminejad Aet al (2020) Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report. Oxf Med Case Reports (6): omaa042. https:\/\/doi.org\/10.1093\/omcr\/omaa042","DOI":"10.1093\/omcr\/omaa042"},{"key":"3270_CR17","doi-asserted-by":"publisher","unstructured":"Fernando EZ, Yu JRT, Santos SMA et al (2021) Involuntary movements following administration of hydroxychloroquine for COVID-19 pneumonia. J Mov Disord 14(1):75\u201377. https:\/\/doi.org\/10.14802\/jmd.20091","DOI":"10.14802\/jmd.20091"},{"issue":"1","key":"3270_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/cod.13657","volume":"84","author":"A Castro Jim\u00e9nez","year":"2021","unstructured":"Castro Jim\u00e9nez A, Navarette NN, Gomez ARG et al (2021) First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test. Contact Dermatitis 84(1):50\u201351. https:\/\/doi.org\/10.1111\/cod.13657","journal-title":"Contact Dermatitis"},{"issue":"1","key":"3270_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4269\/ajtmh.20-0376","volume":"103","author":"R Asli","year":"2020","unstructured":"Asli R, Abdullah MS, Chong PL et al (2020) Case report: right bundle brunch block and QTc prolongation in a patient with COVID-19 treated with hydroxychloroquine. Am J Trop Med Hyg 103(1):79\u201382. https:\/\/doi.org\/10.4269\/ajtmh.20-0376","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"3270_CR20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9151","volume":"12","author":"J Patel","year":"2020","unstructured":"Patel J, Patel R, Rodriguez L et al (2020) Cardiovascular considerations of experimental hydroxychloroquine therapy on patients diagnosed with COVID-19: a case series review. Cureus 12(7):e9151. https:\/\/doi.org\/10.7759\/cureus.9151","journal-title":"Cureus"},{"issue":"3","key":"3270_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/ejh.13432","volume":"105","author":"Y Beauverd","year":"2020","unstructured":"Beauverd Y, Adam Y, Assouline B et al (2020) COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol 105(3):357\u2013359. https:\/\/doi.org\/10.1111\/ejh.13432","journal-title":"Eur J Haematol"},{"key":"3270_CR22","doi-asserted-by":"publisher","unstructured":"Delaleu J, Deniau B, Battistella M et al (2020) Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.\u00a0J Allergy Clin Immunol Pract.\u00a08(8): 2777\u20132779. https:\/\/doi.org\/10.1016\/j.jaip.2020.05.046","DOI":"10.1016\/j.jaip.2020.05.046"},{"issue":"8","key":"3270_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/M20-4207","volume":"173","author":"CP Skipper","year":"2020","unstructured":"Skipper CP, Pastick KA, Engen NW et al (2020) Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med 173(8):623\u2013631. https:\/\/doi.org\/10.7326\/M20-4207","journal-title":"Ann Intern Med"},{"key":"3270_CR24","doi-asserted-by":"publisher","unstructured":"Tang W, Cao Z, Han M et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. bmj 369. https:\/\/doi.org\/10.1136\/bmj.m1849","DOI":"10.1136\/bmj.m1849"},{"issue":"4\u20136","key":"3270_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/01913123.2020.1850966","volume":"44","author":"M Obeidat","year":"2020","unstructured":"Obeidat M, Isaacson AL, Chen SJ et al (2020) Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury? Ultrastruct Pathol 44(4\u20136):519\u2013523. https:\/\/doi.org\/10.1080\/01913123.2020.1850966","journal-title":"Ultrastruct Pathol"},{"issue":"9","key":"3270_CR26","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.hrthm.2020.04.046","volume":"17","author":"Y Szekely","year":"2020","unstructured":"Szekely Y, Lichter Y, Shrkihe BA et al (2020) Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. Heart Rhythm 17(9):1452\u20131455. https:\/\/doi.org\/10.1016\/j.hrthm.2020.04.046","journal-title":"Heart Rhythm"},{"key":"3270_CR27","doi-asserted-by":"publisher","unstructured":"Benjelloun R, Otheman Y, Kettani CE (2020) Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. Pan Afr Med J. 35(Suppl 2):83. https:\/\/doi.org\/10.11604\/pamj.supp.2020.35.24064","DOI":"10.11604\/pamj.supp.2020.35.24064"},{"key":"3270_CR28","doi-asserted-by":"publisher","unstructured":"Semedo E, Kapel GF, Opstal JV et al (2020) Drug-induced \u2018torsade de pointes\u2019 in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European Heart Journal-Case Reports 4(FI1):1\u20135.https:\/\/doi.org\/10.1093\/ehjcr\/ytaa218","DOI":"10.1093\/ehjcr\/ytaa218"},{"issue":"17","key":"3270_CR29","doi-asserted-by":"publisher","first-page":"E612","DOI":"10.1503\/cmaj.210300","volume":"193","author":"LB Day","year":"2021","unstructured":"Day LB, Abdel-Qadir H, Fralick M (2021) Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. CMAJ 193(17):E612\u2013E615. https:\/\/doi.org\/10.1503\/cmaj.210300","journal-title":"CMAJ"},{"issue":"10","key":"3270_CR30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11132","volume":"12","author":"AK Gupta","year":"2020","unstructured":"Gupta AK, Parker BM, Priyadarshi V et al (2020) Cardiac adverse events with remdesivir in COVID-19 infection. Cureus 12(10):e11132. https:\/\/doi.org\/10.7759\/cureus.11132","journal-title":"Cureus"},{"issue":"7","key":"3270_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/cid\/ciaa883","volume":"72","author":"E Leegwater","year":"2021","unstructured":"Leegwater E, Strik A, Wilms EB et al (2021) Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with P-glycoprotein inhibitors. Clin Infect Dis 72(7):1256\u20131258. https:\/\/doi.org\/10.1093\/cid\/ciaa883","journal-title":"Clin Infect Dis"},{"issue":"14","key":"3270_CR32","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.jaccas.2020.08.025","volume":"2","author":"JC Gubitosa","year":"2020","unstructured":"Gubitosa JC, Kakar P, Gerula C et al (2020) Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep 2(14):2260\u20132264","journal-title":"JACC Case Rep"},{"issue":"2","key":"3270_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/jcdd8020018","volume":"8","author":"F Barkas","year":"2021","unstructured":"Barkas F, Styla CP, Bechlioulis A et al (2021) Sinus bradycardia associated with remdesivir treatment in COVID-19: a case report and literature review. J Cardiovasc Dev Dis 8(2):18. https:\/\/doi.org\/10.3390\/jcdd8020018","journal-title":"J Cardiovasc Dev Dis"},{"issue":"11","key":"3270_CR34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/phar.2464","volume":"40","author":"C Carothers","year":"2020","unstructured":"Carothers C, Birrer K, Vo M (2020) Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: a case series. Pharmacotherapy 40(11):1166\u20131171. https:\/\/doi.org\/10.1002\/phar.2464","journal-title":"Pharmacotherapy"},{"issue":"11","key":"3270_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324(11):1048\u20131057. https:\/\/doi.org\/10.1001\/jama.2020.16349","journal-title":"JAMA"},{"issue":"18","key":"3270_CR36","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2169\/internalmedicine.5377-20","volume":"59","author":"R Hase","year":"2020","unstructured":"Hase R, Kurata R, Ishida K et al (2020) Acute gouty arthritis during favipiravir treatment for coronavirus disease 2019. Intern Med 59(18):2327\u20132329. https:\/\/doi.org\/10.2169\/internalmedicine.5377-20","journal-title":"Intern Med"},{"issue":"22","key":"3270_CR37","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.2169\/internalmedicine.5394-20","volume":"59","author":"T Kurita","year":"2020","unstructured":"Kurita T, Ishida K, Muranaka E et al (2020) A favipiravir-induced fever in a patient with COVID-19. Intern Med 59(22):2951\u20132953. https:\/\/doi.org\/10.2169\/internalmedicine.5394-20","journal-title":"Intern Med"},{"issue":"2","key":"3270_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jiac.2020.12.021","volume":"27","author":"S Yamazaki","year":"2021","unstructured":"Yamazaki S, Suzuki T, Sayama M et al (2021) Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. J Infect Chemother 27(2):390\u2013392. https:\/\/doi.org\/10.1016\/j.jiac.2020.12.021","journal-title":"J Infect Chemother"},{"key":"3270_CR39","first-page":"88","volume":"69","author":"P Nasa","year":"2021","unstructured":"Nasa P, Shrivastava P, Kulkarni A et al (2021) Favipiravir induced nephrotoxicity in two patients of COVID-19. J Assoc Physicians India 69:88","journal-title":"J Assoc Physicians India"},{"key":"3270_CR40","doi-asserted-by":"publisher","unstructured":"Ivashchenko AA, Dmitriev KA, Vostokova NV et al (2020) AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial. medRxiv. https:\/\/doi.org\/10.1101\/2020.07.26.20154724","DOI":"10.1101\/2020.07.26.20154724"},{"key":"3270_CR41","doi-asserted-by":"publisher","unstructured":"Udwadia ZF, Singh P, Barkate H et al (2021) Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. International Journal of Infectious Diseases 103:62\u201371.https:\/\/doi.org\/10.1016\/j.ijid.2020.11.142","DOI":"10.1016\/j.ijid.2020.11.142"},{"key":"3270_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.13183","volume":"00","author":"S Zhu","year":"2020","unstructured":"Zhu S, Wang J, Wang Y et al (2020) QTc prolongation during antiviral therapy in two COVID-19 patients. J Clin Pharm Ther 00:1\u20134. https:\/\/doi.org\/10.1111\/jcpt.13183","journal-title":"J Clin Pharm Ther"},{"issue":"FI1","key":"3270_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa171","volume":"4","author":"LY Wang","year":"2020","unstructured":"Wang LY, Ng GYP (2020) COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report. Eur Heart J Case Rep 4(FI1):1\u20136. https:\/\/doi.org\/10.1093\/ehjcr\/ytaa171","journal-title":"Eur Heart J Case Rep"},{"issue":"1","key":"3270_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jmii.2020.07.015","volume":"54","author":"V Shree","year":"2020","unstructured":"Shree V, Liew LQE, Teo WW et al (2020) Potentially fatal severe brady arrythmias related to lopinavir-ritonavir in a COVID 19 patient. J Microbiol Immunol Infect 54(1):133\u2013135. https:\/\/doi.org\/10.1016\/j.jmii.2020.07.015","journal-title":"J Microbiol Immunol Infect"},{"key":"3270_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116944","volume":"415","author":"MM Serrano","year":"2020","unstructured":"Serrano MM, P\u00e9rez-S\u00e1nchez JR, S\u00e1nchez SP et al (2020) Serotonin syndrome in two COVID-19 patients treated with lopinavir\/ritonavir. J Neurol Sci 415:116944. https:\/\/doi.org\/10.1016\/j.jns.2020.116944","journal-title":"J Neurol Sci"},{"key":"3270_CR46","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.19.20038984","author":"Y Li","year":"2020","unstructured":"Li Y, Xie Z, Lin W et al (2020) An exploratory randomized, controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI). MedRxiv. https:\/\/doi.org\/10.1101\/2020.03.19.20038984","journal-title":"MedRxiv"},{"key":"3270_CR47","doi-asserted-by":"publisher","unstructured":"Chaccour C, Casellas A, Blanco-Di Matteo A et al (2020) The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. https:\/\/doi.org\/10.21203\/rs.3.rs-116547\/v1","DOI":"10.21203\/rs.3.rs-116547\/v1"},{"issue":"14","key":"3270_CR48","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","volume":"325","author":"E L\u00f3pez-Medina","year":"2021","unstructured":"L\u00f3pez-Medina E, L\u00f3pez P, Hurtado IC et al (2021) Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 325(14):1426\u20131435. https:\/\/doi.org\/10.1001\/jama.2021.3071","journal-title":"JAMA"},{"issue":"22","key":"3270_CR49","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2169\/internalmedicine.5244-20","volume":"59","author":"H Nakamura","year":"2021","unstructured":"Nakamura H, Miyagi K, Otsuki M et al (2021) Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. Intern Med 59(22):2945\u20132949. https:\/\/doi.org\/10.2169\/internalmedicine.5244-20","journal-title":"Intern Med"},{"issue":"10","key":"3270_CR50","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jmv.25907","volume":"92","author":"AR Morrison","year":"2020","unstructured":"Morrison AR, Johnson JM, Ramesh M et al (2020) Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. J Med Virol 92(10):1791\u20131792. https:\/\/doi.org\/10.1002\/jmv.25907","journal-title":"J Med Virol"},{"issue":"8","key":"3270_CR51","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1111\/liv.14516","volume":"40","author":"D Muhovi\u0107","year":"2020","unstructured":"Muhovi\u0107 D, Bojovi\u0107 J, Bulatovi\u0107 A et al (2020) First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int 40(8):1901\u20131905. https:\/\/doi.org\/10.1111\/liv.14516","journal-title":"Liver Int"},{"key":"3270_CR52","doi-asserted-by":"publisher","unstructured":"Bernardo L, Sesto Del S, Giordano L et al (2020) Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: A case report and brief review of the literature. Drugs & Therapy Perspectives 1\u20135 https:\/\/doi.org\/10.1007\/s40267-020-00777-z","DOI":"10.1007\/s40267-020-00777-z"},{"key":"3270_CR53","doi-asserted-by":"publisher","unstructured":"Wang D, Fu B, Peng Z et al (2021) Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med 1\u20139 https:\/\/doi.org\/10.1007\/s11684-020-0824-3","DOI":"10.1007\/s11684-020-0824-3"},{"issue":"1139","key":"3270_CR54","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/postgradmedj-2020-137785","volume":"96","author":"N Sinha","year":"2020","unstructured":"Sinha N, Balayla G (2020) Hydroxychloroquine and COVID-19. Postgrad Med J 96(1139):550\u2013555. https:\/\/doi.org\/10.1136\/postgradmedj-2020-137785","journal-title":"Postgrad Med J"},{"key":"3270_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2721-8","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Wang Y, Agostinis P et al (2020) Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis 11:1\u20136. https:\/\/doi.org\/10.1038\/s41419-020-2721-8","journal-title":"Cell Death Dis"},{"issue":"5","key":"3270_CR56","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1096\/fj.202000919","volume":"34","author":"EA Meyerowitz","year":"2020","unstructured":"Meyerowitz EA, Vannier AGL, Friesen MGN et al (2020) Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 34(5):6027\u20136037. https:\/\/doi.org\/10.1096\/fj.202000919","journal-title":"FASEB J"},{"key":"3270_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40495-020-00231-8","volume":"6","author":"S Satarker","year":"2020","unstructured":"Satarker S, Ahuja T, Banerjee M et al (2020) Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2. Current Pharmacology Reports 6:203\u2013211. https:\/\/doi.org\/10.1007\/s40495-020-00231-8","journal-title":"Current Pharmacology Reports"},{"issue":"15","key":"3270_CR58","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71(15):732\u2013739. https:\/\/doi.org\/10.1093\/cid\/ciaa237","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3270_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery 6(1):1\u20134. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell discovery"},{"key":"3270_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 34:101615. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101615","journal-title":"Travel Med Infect Dis"},{"issue":"20","key":"3270_CR61","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E et al (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295(20):6785\u20136797. https:\/\/doi.org\/10.1074\/jbc.RA120.013679","journal-title":"J Biol Chem"},{"key":"3270_CR62","doi-asserted-by":"publisher","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V et al (2021) Remdesivir against COVID-19 and other viral diseases. Clinical microbiology reviews 34(1). https:\/\/doi.org\/10.1128\/CMR.00162-20","DOI":"10.1128\/CMR.00162-20"},{"issue":"2","key":"3270_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/scipharm88020029","volume":"88","author":"NF Al-Tannak","year":"2020","unstructured":"Al-Tannak NF, Novotny L, Alhunayan A (2020) Remdesivir\u2014bringing hope for COVID-19 treatment. Sci Pharm 88(2):29. https:\/\/doi.org\/10.3390\/scipharm88020029","journal-title":"Sci Pharm"},{"key":"3270_CR64","unstructured":"FDA approves first treatment for COVID-19 administration (2020) U.S.F.a.D. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19. Accessed 6 June 2021"},{"key":"3270_CR65","doi-asserted-by":"publisher","unstructured":"Touafchia A, Bagheri H, Carri\u00e9 D et al (2021) Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clinical Microbiology and Infection 27(5):791. e5\u2013791. e8. https:\/\/doi.org\/10.1016\/j.cmi.2021.02.013","DOI":"10.1016\/j.cmi.2021.02.013"},{"key":"3270_CR66","unstructured":"LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (2016) Amiodarone.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548109\/. Accessed 8 November 2021"},{"key":"3270_CR67","unstructured":"LiverTox: clinical and research information on drug induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (2020) Remdesivir. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564049\/. Accessed 8 November 2021"},{"key":"3270_CR68","doi-asserted-by":"publisher","unstructured":"Aleem A, Mahadevaiah G, Shariff N et al (2021) Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. in Baylor University Medical Center Proceedings. Taylor & Francis 34(4):473\u2013477. https:\/\/doi.org\/10.1080\/08998280.2021.1885289","DOI":"10.1080\/08998280.2021.1885289"},{"key":"3270_CR69","doi-asserted-by":"publisher","unstructured":"Hashemian SM, Farhadi T, Velayati AA (2020) A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Expert review of anti-infective therapy 19(8):1029\u20131037 .https:\/\/doi.org\/10.1080\/14787210.2021.1866545","DOI":"10.1080\/14787210.2021.1866545"},{"key":"3270_CR70","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"S Joshi","year":"2020","unstructured":"Joshi S, Parkar J, Ansari A et al (2020) Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 102:501\u2013508. https:\/\/doi.org\/10.1016\/j.ijid.2020.10.069","journal-title":"Int J Infect Dis"},{"issue":"4","key":"3270_CR71","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","volume":"76","author":"U Agrawal","year":"2020","unstructured":"Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: a new and emerging antiviral option in COVID-19. Medical Journal Armed Forces India 76(4):370\u2013376. https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004","journal-title":"Medical Journal Armed Forces India"},{"key":"3270_CR72","unstructured":"Reuters (2020) Glenmark gets India approval for favipiravir as COVID-19 treatment. https:\/\/www.reuters.com\/article\/us-health-coronavirus-glenmark-pharms-idUSKBN23Q2E9. Accessed 6 June 2021"},{"key":"3270_CR73","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.2147\/IDR.S287934","volume":"13","author":"RJ Kaur","year":"2020","unstructured":"Kaur RJ, Charan J, Dutta S et al (2020) Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infection and drug resistance 13:4427. https:\/\/doi.org\/10.2147\/IDR.S287934","journal-title":"Infection and drug resistance"},{"issue":"1","key":"3270_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bj.2020.11.005","volume":"44","author":"P Magro","year":"2020","unstructured":"Magro P, Zanella I, Pescarolo M et al (2020) Lopinavir\/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. J Biomed 44(1):43\u201353. https:\/\/doi.org\/10.1016\/j.bj.2020.11.005","journal-title":"J Biomed"},{"issue":"8","key":"3270_CR75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/13543784.2020.1777277","volume":"29","author":"SA Doggrell","year":"2020","unstructured":"Doggrell SA (2020) Does lopinavir measure up in the treatment of COVID-19? Expert Opin Investig Drugs 29(8):793\u2013796. https:\/\/doi.org\/10.1080\/13543784.2020.1777277","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"3270_CR76","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/1440-1681.13425","volume":"48","author":"J Qu","year":"2021","unstructured":"Qu J, Li GH, Wang JJ et al (2021) Comparative effectiveness of lopinavir\/ritonavir-based regimens in COVID-19. Clin Exp Pharmacol Physiol 48(2):203\u2013210. https:\/\/doi.org\/10.1111\/1440-1681.13425","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"Suppl 1","key":"3270_CR77","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.3904\/kjim.2020.224","volume":"36","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim EJ, Kwon HH et al (2021) Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. Korean J Intern Med 36(Suppl 1):S253. https:\/\/doi.org\/10.3904\/kjim.2020.224","journal-title":"Korean J Intern Med"},{"key":"3270_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110267","volume":"128","author":"R Salvi","year":"2020","unstructured":"Salvi R, Patankar P (2020) Emerging pharmacotherapies for COVID-19. Biomed Pharmacother 128:110267. https:\/\/doi.org\/10.1016\/j.biopha.2020.110267","journal-title":"Biomed Pharmacother"},{"issue":"27","key":"3270_CR79","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"M Costanzo","year":"2020","unstructured":"Costanzo M, De Giglio MA, Roviello GN (2020) SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 27(27):4536\u20134541. https:\/\/doi.org\/10.2174\/0929867327666200416131117","journal-title":"Curr Med Chem"},{"issue":"9","key":"3270_CR80","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00228-021-03108-x","volume":"77","author":"N von Hentig","year":"2021","unstructured":"von Hentig N (2021) Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. Eur J Clin Pharmacol 77(9):1297\u20131307. https:\/\/doi.org\/10.1007\/s00228-021-03108-x","journal-title":"Eur J Clin Pharmacol"},{"key":"3270_CR81","doi-asserted-by":"publisher","unstructured":"Dixit A, Yadav R, Singh AV (2020) Ivermectin: potential role as repurposed drug for COVID-19. The Malaysian journal of medical sciences: MJMS 27(4):154. https:\/\/doi.org\/10.21315\/mjms2020.27.4.15","DOI":"10.21315\/mjms2020.27.4.15"},{"key":"3270_CR82","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3389\/fimmu.2021.663586","volume":"12","author":"Z Wehbe","year":"2021","unstructured":"Wehbe Z, Wehbe M, Iratni R et al (2021) Repurposing ivermectin for COVID-19: molecular aspects and therapeutic possibilities. Front Immunol 12:1040. https:\/\/doi.org\/10.3389\/fimmu.2021.663586","journal-title":"Front Immunol"},{"issue":"1","key":"3270_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06104-9","volume":"21","author":"N Okumu\u015f","year":"2021","unstructured":"Okumu\u015f N, Demirt\u00fcrk N, \u00c7etinkaya RA et al (2021) Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis 21(1):1\u201311. https:\/\/doi.org\/10.1186\/s12879-021-06104-9","journal-title":"BMC Infect Dis"},{"key":"3270_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.007","author":"L Shahbaznejad","year":"2021","unstructured":"Shahbaznejad L, Davoudi M, Eslami G et al (2021) Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial. Clin Ther. https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.007","journal-title":"Clin Ther"},{"issue":"48","key":"3270_CR85","doi-asserted-by":"publisher","first-page":"30025","DOI":"10.1073\/pnas.2009253117","volume":"117","author":"C Yang","year":"2020","unstructured":"Yang C, Liu E, Liu M (2020) Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients. Proc Natl Acad Sci 117(48):30025\u201330026. https:\/\/doi.org\/10.1073\/pnas.2009253117","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3270_CR86","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40261-020-00917-3","volume":"40","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li L, Shen A et al (2020) Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 40(6):511\u2013518. https:\/\/doi.org\/10.1007\/s40261-020-00917-3","journal-title":"Clin Drug Investig"},{"issue":"2","key":"3270_CR87","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1574891X15666200922155712","volume":"15","author":"A Ali","year":"2020","unstructured":"Ali A, Kamjani MH, Kesselman MM (2020) The role of tocilizumab in cytokine storm and improving outcomes in COVID-19. Recent Pat Anti-Infect Drug Discovery 15(2):104\u2013112. https:\/\/doi.org\/10.2174\/1574891X15666200922155712","journal-title":"Recent Pat Anti-Infect Drug Discovery"},{"issue":"6","key":"3270_CR88","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","volume":"51","author":"A Saha","year":"2020","unstructured":"Saha A, Sharma AR, Bhattacharya M et al (2020) Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res 51(6):595\u2013597. https:\/\/doi.org\/10.1016\/j.arcmed.2020.05.009","journal-title":"Arch Med Res"},{"issue":"3","key":"3270_CR89","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5005\/jp-journals-10071-23747","volume":"25","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, Rankawat G, Singh G (2021) Tocilizumab: an effective therapy for severely and critically ill COVID-19 patients. Indian Journal of Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine 25(3):260\u2013266. https:\/\/doi.org\/10.5005\/jp-journals-10071-23747","journal-title":"Indian Journal of Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine"},{"key":"3270_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li JW et al (2020) The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105954","journal-title":"Int J Antimicrob Agents"},{"issue":"10285","key":"3270_CR91","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285):1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"issue":"10274","key":"3270_CR92","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10274):605\u2013612. https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5","journal-title":"The Lancet"},{"key":"3270_CR93","doi-asserted-by":"publisher","unstructured":"E Wilkinson 2020 RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials BMJ 369 https:\/\/doi.org\/10.1136\/bmj.m1626","DOI":"10.1136\/bmj.m1626"},{"issue":"6","key":"3270_CR94","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM et al (2021) Repurposed antiviral drugs for COVID-19\u2014interim WHO solidarity trial results. N Engl J Med 384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"3270_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0","author":"F Ader","year":"2021","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M et al (2021) Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0","journal-title":"Lancet Infect Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03270-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:06:56Z","timestamp":1649750816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03270-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03270-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}